ArticleWide range of chromosome abnormalities in the embryos of young egg donors
Section snippets
Santiago Munní has been director of PGD at Reprogenetics since 2001. This company, which he founded, offers PGD services to over 150 IVF centers in the US, and also has labs in Spain and Japan. Originally from Barcelona, Spain, Dr Munní gained his PhD in genetics from the University of Pittsburgh and joined Dr Jacques Cohen at Cornell University Medical College, New York in 1991. There he developed the first PGD test to detect embryonic numerical chromosome abnormalities. His work has been
References (32)
- et al.
Clinical value of preimplantiation genetic diagnosis
Placenta
(2003) - et al.
Preimplantation diagnosis for aneuploidies in patients undergoing in vitro fertilization with a poor prognosis: identification of the categories for which it should be proposed
Fertility and Sterility
(1999) - et al.
Cell differentiation in the preimplantation human embryo
Reproductive BioMedicine Online
(2003) - et al.
Preimplantation genetic diagnosis reduces pregnancy loss in women 35 and older with a history of recurrent miscarriages
Fertility and Sterility
(2005) - et al.
Differences in chromosome susceptibility to aneuploidy and survival to first trimester
Reproductive BioMedicine Online
(2004) - et al.
Improved implantation after preimplantation genetic diagnosis of aneuploidy
Reproductive BioMedicine Online
(2003) - et al.
Embryo morphology, developmental rates and maternal age are correlated with chromosome abnormalities
Fertility and Sterility
(1995) - et al.
In vitro fertilization plus preimplantation genetic diagnosis in patients with recurrent miscarriage: an analysis of chromosome abnormalities in human preimplantation embryos
Fertility and Sterility
(1999) - et al.
Preimplantation genetic diagnosis for aneuploidy screening in patients with unexplained recurrent miscarriages
Fertility and Sterility
(2005) - et al.
High frequency of chromosomal abnormalities in embryos obtained from oocyte donation cycles
Fertility and Sterility
(2003)
Chromosomal abnormalities in embryos derived from TESE
Fertility and Sterility
Blastomere fixation techniques and risk of misdiagnosis for PGD of aneuploidy
Reproductive BioMedicine Online
Preimplantation aneuploidy screening using comparative genomic hybridization or fluorescence in situ hybridization of embryos from patients with recurrent implantation failure
Fertility and Sterility
Chromosomal mosaicism throughout human preimplantation development in vitro: incidence, type, and relevance to embryo outcome
Human Reproduction
Comment 2 on Staessen et al. 2004 Two-cell biopsy and PGD pregnancy outcome
Human Reproduction
PGD analysis for aneuploidy in a patient heterozygous for a polymorphism of chromosome 16 (16qh-)
Prenatal Diagnosis
Cited by (82)
Clinical outcomes after the transfer of blastocysts characterized as mosaic by high resolution Next Generation Sequencing- further insights
2020, European Journal of Medical GeneticsTelomeres and genomic instability during early development
2020, European Journal of Medical GeneticsCitation Excerpt :Genomic instability is rampant during human preimplantation embryo development (Munne et al., 2006).
Innovations in assisted reproductive technologies: impact on contemporary donor egg practice and future advances
2018, Fertility and SterilityCitation Excerpt :Historically, egg donor cycles have resulted in transfer of PGT-untested embryos. While donor oocyte cycles typically result in high pregnancy and live birth rates due to the young age of the donor, prior studies have shown that up to one third of embryos derived from donor oocytes are aneuploid (41, 42). In a retrospective cross-sectional study of U.S. data from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System from 2005 to 2013, live birth rates were significantly lower for PGT-A (51.8%) than control cycles (59.9%, P=.001).
Impact of preimplantation genetic screening on donor oocyte-recipient cycles in the United States
2017, American Journal of Obstetrics and Gynecology
Santiago Munní has been director of PGD at Reprogenetics since 2001. This company, which he founded, offers PGD services to over 150 IVF centers in the US, and also has labs in Spain and Japan. Originally from Barcelona, Spain, Dr Munní gained his PhD in genetics from the University of Pittsburgh and joined Dr Jacques Cohen at Cornell University Medical College, New York in 1991. There he developed the first PGD test to detect embryonic numerical chromosome abnormalities. His work has been recognized by several prizes: in 1994, 1995, 1998 and 2005 from the Society for Assisted Reproductive Technology, and in 1996 from the American Society for Reproductive Medicine. Recently the PGD team has shown higher pregnancy rates and lower spontaneous rates in women of advanced age undergoing PGD. This team has performed more than 700 PGD cycles for translocations and over 5500 PGD cycles for chromosome abnormalities related to advanced maternal age or with recurrent pregnancy loss. Dr Munní has more than 150 publications to his name, and is a frequent lecturer, both nationally and internationally, on his team's work and the field of preimplantation genetics. He was recently blessed with his first daughter, Mar.